Survival in Patients Undergoing Allogeneic Stem Cell Transplantation

Survival in Patients Undergoing Allogeneic Stem Cell Transplantation: An Institutional Experience Justin Jiang 1; Audrey M. Sigmund, MD 2; Qiuhong Zhao, MS 2; Patrick Elder, MS 2; Yvonne A. Efebera, MD, MPH 2; Nidhi Sharma 2 1 The Ohio State College of Medicine, Columbus, OH; 2 Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute October 13 th, 2020

Background § Allogeneic Stem Transplantation (allo-SCT) can be a potentially curative treatment for hematological disorders § Major complications include: § graft-versus-host disease (GVHD) § relapse of disease § infectious complications § Improvements made to produce better outcomes include: § Advancements in conditioning regimens § GVHD prophylaxis § Infectious disease monitoring/prophylaxis 2

Methods § Retrospective analysis of patient undergoing allo-SCT from 19862018 at OSUCCC (n = 1943) § Seven groups – groups (gp) 1: 1984 -1988, 2: 1989 -1993, 3: 19941998, 4: 1999 -2003, 5: 2004 -2008, 6: 2009 -2013, and 7: 20142018. § Overall survival (OS) and progression free survival (PFS) estimated with Kaplan-Meier and compared with log-rank test 3

Results Progression Free Survival 4 Overall Survival

Results Acute GVHD, Grade 2 -4 5 Cumulative Incidence of NRM

Conclusions § Advances in supportive care and GVHD prophylaxis attributed to improved OS and PFS § Decline in NRM likely the result of improved infectious disease monitoring and prophylaxis § Post-transplant relapse and high grade a. GVHD continue to be a challenge in improving allo-SCT outcomes 6

Acknowledgements § I would like acknowledge the support of the Bennet Medical Student Research Scholarship as well as thank Drs. Nidhi Sharma and Yvonne Efebera for their mentorship and guidance in this project 7

Thank You To learn more about Ohio State’s cancer program, please visit cancer. osu. edu or follow us in social media: 8